RxDoctor Payments DataLook up a doctor →

Vipul Dev, MD

Plastic Surgery · Bakersfield, CANPI 1891702122

Payments from drug & device makers

$1,069,609in general payments, 2019–2025

Across 663 payments — averaging $1613.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$1.1M
  • Smith+Nephew$4K
  • Polarityte, Inc.$2K
  • Nevro Corp.$618
  • Stimlabs LLC$503
  • Mentor Worldwide LLC$434
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$892,88783%
  • Speaking & faculty fees$128,62212%
  • Travel & lodging$34,8063%
  • Food & beverage$13,2901%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,069,609 in reported general payments places this provider in the 95th percentile of 780 plastic surgery providers in California.

See all plastic surgery providers in California

Medicare billing

Part B allowed, 2024
$156,363
Medicare patients
179
Services billed
1,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gentamicin Sulfate136$9,960
SantylCollagenase Clostridium Hist.13$4,863
Diflorasone Diacetate11$3,528
Calcipotriene15$3,245
SsdSilver Sulfadiazine90$1,590
Fluorouracil17$1,259
Cephalexin107$742
Silver Sulfadiazine49$652
Diclofenac Sodium57$562
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim90$387
Mupirocin22$289
Clindamycin Hcl24$253
Levofloxacin15$210
Hydroxyzine Hcl13$206
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$4,219$4,86313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 780 plastic surgery providers in California.

Other plastic surgery in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →